QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaccinex-granted-us-patent-12070500----use-of-semaphorin-4d-antibodies-in-combination-with-an-immune-modulating-therapy-to-inhibit-tumor-growth-and-metastasis

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12070500?requestToken=eyJzdWIiOiJiYzJlZmQ2Zi1mMTk5LTQwZDMtOGZhN...

 vaccinex-shares-resume-trade
Vaccinex Shares Resume Trade
07/31/2024 14:11:25

 vaccinex-announces-early-stage-signal-ad-trial-results-for-pepinemab-antibody-in-alzheimers-disease-findings-show-novel-mechanism-targeting-astrocyte-activation-delays-disease-progression

Results Echo Phase 2 Huntington's Disease Study; Presented By Principal Investigator Eric Siemers, MD, At Alzheimer's A...

 vaccinex-to-report-topline-data-for-signal-ad-phase-1b2-trial-of-pepinemab-in-alzheimers-disease-at-the-alzheimers-association-international-conference-philadelphia-july-31-2024

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer...

 vaccinex-shares-resume-trade
Vaccinex Shares Resume Trade
05/31/2024 13:43:59

 vaccinex-q1-eps-294-sales-10400k-down-from-55000k-yoy

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(2.94) per share. The company reported $104.00 thousand in sales this quar...

 vaccinex-q4-eps-033-up-from-2310-yoy

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(0.33) per share. This is a 98.57 percent increase over losses of $(23.10)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION